|
Jun 27
|
Exploring Three High Growth Tech Stocks In The US Market
|
|
Jun 27
|
Exploring 3 High Growth Tech Stocks in the US Market
|
|
Jun 26
|
Exploring High Growth Tech Stocks In The US Market
|
|
Jun 25
|
Exploring US High Growth Tech Stocks For Potential Opportunities
|
|
Jun 25
|
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
|
|
Jun 25
|
US High Growth Tech Stocks To Watch In June 2025
|
|
Jun 24
|
High Growth Tech Stocks To Watch In US June 2025
|
|
Jun 24
|
Exploring US High Growth Tech Stocks To Watch In June 2025
|
|
Jun 24
|
Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook
|
|
Jun 23
|
High Growth Tech Stocks in US for June 2025
|
|
May 14
|
Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term
|
|
May 13
|
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
|
|
May 12
|
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
|
|
May 6
|
Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1
|
|
May 5
|
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025
|
|
Jul 24
|
Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year
|
|
Jun 24
|
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
|
|
Jun 21
|
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
|
|
May 15
|
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
|
|
May 15
|
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
|